ALK and cancer: The latest NSCLC guideline, 2019 v3, published by national comprehensive cancer network (NCCN) suggests that 9 genes related to targeted therapy should be detected, including EGFR, KRAS, HER2, ALK, ROS1, MET, BRAF, RET, and NTRK.